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Abstract
Background: Use of the atypical antipsychotic sertindole was suspended for four years due to safety concerns. During
the suspension, the regulatory authorities required further studies, including this one, to be conducted. The purpose of
this study was to determine if a subset of patients with psychotic illness exists which particularly benefits from sertindole
treatment after failure of other antipsychotic drugs, including atypical antipsychotics.
Methods: This was a retrospective single-arm observational crossover study of 344 patients, who served as their own
controls. Patients mainly from the Sertindole Safety Study who had shown good response to sertindole, and who had
followed up to four alternating six month periods of treatment with sertindole and other antipsychotics, were included.
(In Period 1 patients took non-sertindole treatment, in Period 2, sertindole was taken, in Period 3, patients reverted to
non-sertindole treatment, and in Period 4, sertindole was taken again.) Patient records for each period of treatment were
assessed for objective data: number and duration of hospitalizations due to worsening of psychotic symptoms; the
amount of self-harming behaviour; indicators of social status. Retrospective evaluation of changes in clinical symptoms
from the patients' records was also conducted. Dates and reasons for stopping and/or switching medication were also
recorded.
Results: There was improvement in all objective measured parameters during the periods of sertindole treatment. In
particular, the average number of hospitalizations per year due to worsening of psychotic symptoms was reduced in the
following way in the group studied over four treatment periods: Period 1 (non-sertindole treatment) 3.4; Period 2
(sertindole treatment) 1.0; Period 3 (non-sertindole treatment) 2.0; Period 4 (sertindole treatment) 1.8. The duration of
hospitalizations also decreased significantly during the periods of sertindole treatment. Results showed that patients
improved in objective social parameters when switched to sertindole treatment; assessment of the patients' affective lives
showed a significant increase in the number of patients having a stable relationship during sertindole treatment; and
assessment of the number of patients employed showed an increase after the first and second switch to sertindole
treatment (from Period 1 to Period 2 and from Period 3 to Period 4, respectively).
Adverse events and lack of efficacy were the main reasons for switching to sertindole.
Conclusion: A group of patients benefited from sertindole after other antipsychotic treatments, including that with
atypical antipsychotics, had failed. Further studies are needed to investigate if there is a specific patient profile that
corresponds to these responders.
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Background
Schizophrenia is a chronic, complex, and heterogeneous
disease that affects most aspects of psychological func-
tioning. The disease is frequently associated with cogni-
tive and depressive symptoms and commonly manifests
at an early adult age. It can have a devastating impact on
familial, social and vocational aspects of patients' lives [1-
3]. Long-term treatment with antipsychotic drugs is the
major factor in preventing relapse [4-6].
For the patient suffering from schizophrenia it is crucially
important to receive the best possible treatment. The indi-
vidual responses to different treatments are highly varia-
ble, and therefore a wide selection of clinically efficacious
and safe drugs will maximize the chances that the appro-
priate treatment is eventually prescribed to each patient
[7,8].
Although clozapine has been a great improvement in
addressing unmet medical needs for treatment-resistant
patients, it is still thought that many patients with schizo-
phrenia do not respond to any available antipsychotic
treatment [9,10].
Sertindole is an atypical antipsychotic drug indicated for
the treatment of schizophrenia. It was first authorised in
the United Kingdom in 1996 and subsequently in other
European countries. Due to concerns related to cardiac
safety which arose after its launch, the marketing of sertin-
dole was suspended by Lundbeck in November 1998 [11].
In June 1999, the European Committee for Proprietary
Medicinal Products (CPMP, now the CHMP) adopted an
Opinion recommending the temporary suspension of the
Marketing Authorizations for sertindole and asked for a
complementary benefit/risk evaluation of the product
[12]. The present study (the "NICHE" study) was part of
this evaluation. It was performed in order to respond to
the question of whether there is a subset of patients that
clearly improve during sertindole treatment after failure
with other antipsychotics.
This observational study was designed in order to include
patients who had two non-consecutive treatment periods
with sertindole. Since market availability of sertindole
was restricted after the suspension, patients were mainly
selected from those who were identified in a previous sur-
vey, the Sertindole Safety Survey [13] therefore giving the
name the present study, the NICHE study.
The NICHE study provided an opportunity to document
the improvement, or otherwise, of a subset of patients
who had benefited from sertindole treatment, and for
whom alternative therapies had not shown comparable
results. The assessment of safety was not an objective of
this study, as this was addressed in the Sertindole Safety
study.
Methods
Data sources
The 344 patients included were mainly from the Euro-
pean countries that had launched sertindole before its
marketing suspension in 1998. The only exceptions were
patients from France and the UK (where sertindole had
not been launched). For these latter countries, patients
that had been included in long-term clinical trials and
who fitted the predefined profile were selected, account-
ing for 5.6% of the patients in the present study (Table 1).
In order to include patients who had two non-consecutive
treatment periods with sertindole, patients were selected
from those who had been treated through the named-
patient program (set up after sertindole suspension), and
who were identified in a previous survey, the Sertindole
Safety Survey.
The Sertindole Niche Survey is a retrospective study, with
no patient exclusion criteria and no personal identifica-
tion required. For this study there was no need for ethics
committee approval of the study according to the coun-
tries regulations at the time of conduction of this study in
Austria, Belgium, Czech Republic, Estonia, Finland,
France, Germany, Hungary, Latvia, Netherlands and
United Kingdom.
The Sertindole Niche Survey was based on the Sertindole
Safety Survey, for which local regulatory rules were fol-
lowed in each participating country. Where applicable,
the Sertindole Safety Survey study was submitted to and
approved by the relevant authorities and/or local ethics
committee/institutional review board.
Patients were 18 years or older; their primary diagnosis
was that of a psychosis, mainly schizophrenia.
A treatment period of at least six months with the con-
cerned antipsychotic was required (see Figure 1). In the
pre-study initial selection, patients were excluded if they
experienced relapse under sertindole treatment. The
patient population encompassed four possible periods of
antipsychotic treatment (periods 1 to 4, of which two
were with sertindole and two were with other antipsy-
chotic drugs), and three groups of patients (patients who
went through 4, 3 or 2 periods of treatment, respectively).
The age, gender, DSM IV classification, history of psychi-
atric disorder, general medical history, and history of drug
abuse of the patients were recorded before the evaluation.BMC Psychiatry 2008, 8:16 http://www.biomedcentral.com/1471-244X/8/16
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All antipsychotic medication taken within the observa-
tional period was recorded, including the type of drug, the
indication, the dose, the start and end date of treatment,
and the reason for stopping or switching medication.
Concomitant medication was not recorded.
Study design
This was a single-arm, retrospective, crossover study. Data
collection was not blinded and treatments had not been
randomly allocated. The patient served as his or her own
control.
All patients followed alternate periods of antipsychotic
treatments: after an initial treatment period on a non-
sertindole antipsychotic regimen of at least six months,
patients who either were not responding or were experi-
encing tolerability problems, were switched to sertindole
treatment (Figure 1). Following sertindole's market sus-
pension, patients were switched again to other antipsy-
chotics. Subsequently, some of the patients went on to
receive a further period of sertindole treatment, under the
named patient compassionate use programme. Up to four
treatment periods of around six months each were thus
studied. This design thus produced three separate patient
groups from the initial 344 patients: a group of patients
that had experienced only two treatment periods, a group
of patients that had experienced three treatment periods,
and a group of patients that had experienced four treat-
ment periods.
Data analysis
For each treatment period, patient records were assessed
for objective parameters (the number of hospitalizations
and the amount of self-aggression behaviour [self-harm
and suicide attempts]). These data are supportive of the
retrospective data on patient clinical symptoms (meas-
ured by the Clinical Global Impression and Global Assess-
ment Function scales).
The psychiatrist attending each patient retrospectively
assessed the longitudinal course of the psychosis using the
five main symptoms defined in the DSM IV for psychosis
longer than one year (all types considered). These symp-
toms were rated from 0 to 3 according to intensity (0 =
absent, 3 = severe). In addition, the following assessments
and records were used to support the data:
• Clinical symptom evaluation was based on the Clinical
Global Impression (CGI) and the Global Assessment
Function (GAF) scales.
Table 1: Total number of patients per country
Country Number of patients n (%)
Austria 18 (5.2%)
Belgium 54 (15.7%)
Czech Republic 12 (3.5%)
Estonia 2 (0.6%)
Finland 7 (2.0%)
France 15 (4.4%)
Germany 97 (28.2%)
Hungary 55 (16.0%)
Latvia 71 (20.6%)
Netherlands 9 (2.6%)
United Kingdom 4 (1.2%)
Total 344 (100%)
Types of patients and study design Figure 1
Types of patients and study design.
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• The number of hospitalizations and the number of days
in hospital were recorded.
• Self-harming behaviour was assessed by the number of
suicide and self-harm attempts made.
• The presence of a stable personal relationship and the
employment status provided objective information in
support of the social assessments.
Statistical analysis
The statistics were essentially descriptive. The results were
analysed taking into account the score of each individual
item, enabling the comparison of the results between dif-
ferent periods.
Number of hospitalizations, duration of hospitalization,
and number of self-harm and suicide attempts were com-
puted by treatment period. Data were analysed using SAS
software (version 6.12). Quantitative variables were
expressed as mean ± standard deviation (SD), while qual-
itative variables were presented using frequencies and per-
centages. Chi-square tests (or Fisher's exact tests when
appropriate), as well as t-tests (or Mann-Whitney tests
when appropriate) were used to compare qualitative or
quantitative data. All statistical tests were two-sided, with
the α risk set to 0.05.
Results
Patients' profiles at start of study
344 patients were included in this study; 185 (53.8%)
were women and 157 (45.6%) were men (gender was
missing for 2 patients [0.6%]). Of the 344 patients, 57 had
followed four treatment periods (P1–P4). The average age
(± SD) was 39.3 (± 14.2) years. The average duration (±
SD) of the present psychiatric disorder was 11.8 (± 9.1)
years. See Table 2 for the patients' baseline characteristics.
Patients' profiles during the treatment periods
From the patients included in this study, around 17% fol-
lowed four treatment periods. From the remaining
patients, around 45% followed three treatment periods
and around 38% followed two treatment periods. The
number of patients within each group is shown on Figure
2. After the first treatment with sertindole, the average
treatment duration did not change significantly between
periods, ranging from 8.7 ± 5.9 (SD) months in Period 2
to 6.4 ± 4.3 (SD) months in Period 4, as shown in Table 3.
Analysis of the types of antipsychotic drugs taken during
Periods 1 and 3 (the non-sertindole periods) showed an
increase in the percentage of atypical antipsychotics used
over time (Table 4). The most prescribed antipsychotics in
Period 1 were clozapine (24.6%) and risperidone
(24.6%). In Period 3, the most prescribed antipsychotic
was olanzapine (42.1%).
The main reasons for switching to sertindole at the end of
the first treatment period (P1) were found to be firstly,
lack of efficacy, and secondly, experience of adverse events
under the previous treatment.
The main reason for stopping sertindole after Period 2 was
due to its market suspension or consequent difficulties in
supply.
Results from the group that followed four treatment 
periods (P1–P4)
The comparison between adjacent periods shows that the
average number of hospitalizations due to worsening of
Table 2: Patient clinical profile at baseline
Patients' baseline profile Number of patients n (%)
Primary diagnosis
Schizophrenia* 304 (88.6%)
Paranoid type 218 (71.9%)
Disorganized type 31 (10.2%)
Undifferentiated type 29 (9.6%)
Residual type 15 (5.0%)
Catatonic type 10 (3.3%)
Other than schizophrenia 39 (11.4%)
Schizo-affective disorder 19 (51.4%)
Concomitant mental disorders 105 (30.7%)
Mood disorders 76 (72%)
Anxiety and other disorders 88 (83.8%)
Hospitalization due to psychosis 326 (94.8%)
Last hospitalization duration > 1 month 204 (62.5%)
Patients that had been physically violent towards another person at least once 89 (25.9%)
Patients that had attempted self-harm at least once 68 (20.4%)
*data for 1 patient was missingBMC Psychiatry 2008, 8:16 http://www.biomedcentral.com/1471-244X/8/16
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psychotic symptoms was significantly decreased during
the first and second period with sertindole treatment (P2
and P4, respectively). These findings are summarised in
Figure 3. From Periods 1 to 2, duration of hospitalisation
(± SD) was significantly reduced from 134 days (± 106) to
65 days (± 139) (p < 0.05). The duration of hospitaliza-
tion increased to 68 days (± 108) in Period 3, although
this was not statistically different from Period 2. From
Period 3 to Period 4, a significant reduction in duration of
hospitalization was also seen (68 days [± 108] in P3 to 56
days [± 135] in P4, p = 0.019, respectively).
The number of self-harm and suicide attempts was signif-
icantly reduced during both sertindole periods compared
to the non-sertindole periods. After starting the first sertin-
dole treatment the percentage of self-harm attempts
decreased from 22.8% to 3.5% (p < 0.001), and during
the second period of sertindole treatment it reduced from
5.8% to 1.8% (p < 0.05). The number of suicide attempts
also followed this trend with a reduction from 15.8% to
3.5%, and from 7.0% to 0%, during the first and second
sertindole-treatment periods, respectively.
Analyses of patients' affective lives and employment and
occupational statuses showed that patients improved in
objective social parameters when switched to sertindole
treatment, i.e., in Periods 2 and 4 (see Figure 1). Assess-
ment of the patients' affective lives showed a significant
increase in the number of patients engaged in a stable
relationship during sertindole treatment (54.4% in Period
2 and 57.1% in Period 4), compared with the periods of
non-sertindole treatment (38.6% in Period 1 and 45.6%
in Period 3) (Table 5). The number of patients employed
more than doubled from Period 1 to Period 2 (from
14.0% to 31.6%) and also increased, although not statis-
tically significantly, from Period 3 to Period 4 (from
22.8% to 33.9%) (Table 5).
Clinical evaluation data were also supportive of the above
objective results: during sertindole treatment, i.e., in Peri-
ods 2 and 4 (see Figure 1), 26.3% and 21.4% of the
patients, respectively, were found to be in full remission
according to the DSM-IV criteria (Table 6). Clinical evalu-
ation based on clinical scores showed that all the symp-
toms of current psychiatric disorders were on average at a
higher level during Period 1 and 3 than during the sertin-
dole-treatment periods (P2 and P4); during both Periods
1 and 3, the patients were on average moderately to mark-
edly ill on the CGI scale, whereas during both Periods 2
and 4 they were borderline mentally ill to mildly ill. The
mean GAF scores were 35.6 and 44.8 during Periods 1 and
3 respectively, and 61.4 and 65.5 during Periods 2 and 4,
respectively.
Discussion
The results show that there is a subset of patients who
were switched to sertindole that had an improvement in
their clinical symptoms, which was reflected in a decrease
in the number and duration of hospitalizations, as well as
suicide attempts.
When sertindole was first suspended from the market, it
could only be prescribed under the named-patient pro-
gram. Although some clinicians continued to prescribe
sertindole, many patients were switched to other treat-
Table 3: Comparison of duration of treatment periods
Period 2 Period 3 Period 4
Mean duration ± SD (months) 8.7 ± 5.9 7.1 ± 5.2 6.4 ± 4.3
p-value 0.244 0.465
Patients per number of periods experienced Figure 2
Patients per number of periods experienced.
4 periods (P1 -P4)
3 periods only  (P1 -P3)
2 periods only (P1 -P2)
57
(16.6%) 
131
(38.1%) 
156
(45.3%) 
Table 4: Antipsychotic treatment during Period 1 and Period 3
Type of Antipsychotic Period 1 n (%) Period 3 n (%)
Four treatment period group (P1–P4) Only typical antipsychotics 29 (50.9%) 6 (51%)
At least one atypical antipsychotic 28 (49.1%) 51 (89.5%)
Three treatment period group (P1–P3) Only typical antipsychotics 64 (41.0%) 17 (11.0%)
At least one atypical antipsychotic 92 (59.0%) 138 (89.0%)
Two treatment period group (P1–P2) Only typical antipsychotics 14 (10.7%) NA
At least one atypical antipsychotic 117 (89.3%) NABMC Psychiatry 2008, 8:16 http://www.biomedcentral.com/1471-244X/8/16
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ments. From clinical observation, it was suggested that
there might be a subset of patients who respond uniquely
to sertindole [13]. In order to identify whether this pro-
posed subset of patients exists, we conducted this retro-
spective study of the health records of patients who had
received alternate periods of non-sertindole antipsychotic
drug therapy and sertindole therapy. This study was con-
ducted using retrospective methodology, as sertindole
was suspended at the time and it was not possible to run
prospective clinical trials.
This study was not designed to compare antipsychotics,
but to document, in a standardised way, if a subset of
patients exists for whom multiple previous antipsychotic
treatments had not been satisfactory, but who had
improved with sertindole. As a result, the total number of
patients to be included was not calculated. Because the
study was conducted retrospectively, the treatment pat-
tern and patient management were unaffected by the con-
duct of the study. However, the treatments were not
randomly allocated and the reliability of the unblinded
efficacy data may be questioned. Data collection was
therefore standardised for the various assessment periods,
using both objective criteria (number and duration of
hospitalizations, number self-harm and suicide attempts,
patient's affective life and employment and occupational
status) and subjective criteria (the clinical scorings, GAF,
CGI).
Each patient served as his or her own control, and com-
parisons were achieved in crossover periods in the
patients who followed four treatment periods. The results
from the group of patients who followed the four treat-
ment periods provide the strongest possible indicator for
Table 5: Objective Social Assessments
Period 1 Period 2 Period 3 Period 4
Patients' Affective Lives Engaged in a stable relationship 22 (38.6%) 31 (54.4%) 26 (45.6%) 32 (57.1%)
p-value 0.003 0.059 0.014
Employment and Occupational Status Employed most of the time 8 (14.0%) 18 (31.6%) 13 (22.8%) 19 (33.9%)
p-value 0.008 0.096 0.014
Mean number and mean duration of hospitalizations due to worsening of psychotic symptoms in the four treatment period  group Figure 3
Mean number and mean duration of hospitalizations due to worsening of psychotic symptoms in the four 
treatment period group. Mean number of hospitalizations (comparison with previous period): * p < 0.001, **p = 
0.02, #p = 0.001. Mean duration of hospitalizations(comparison with previous period): * p < 0.001, **p = 0.14, #p = 
0.02.BMC Psychiatry 2008, 8:16 http://www.biomedcentral.com/1471-244X/8/16
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the causal relationship between sertindole treatment and
improvement in symptoms. This design could be com-
pared to the challenge-dechallenge-rechallenge strategy in
pharmacovigilance.
Results from the patients who followed only two or three
alternate treatment periods, although confirming what
was observed in the P1–P4 group, have not been reported
here in detail, as they were not the focus of this article. It
would be interesting to analyse the results between these
groups in further studies. The individual clinical results
have not been analysed statistically as the patients were
not randomly selected (only patients who responded to
sertindole treatment were included), and analysis would
have had no value.
The improvements in all criteria during the sertindole
treatment periods provide evidence of a sub-group of
patients who respond particularly well to this drug. In par-
ticular, the reduction in number of hospitalizations due to
worsening of psychotic symptoms provides objective evi-
dence for this improvement, as hospitalization for wors-
ening of psychosis has been demonstrated to be a good
indicator of relapse in patients with schizophrenia [14].
Why a particular subgroup of patients responds to sertin-
dole in this way is unknown, but it may be related to the
specific chemical structure and the specific receptor pro-
file which lead to the unique pharmacological profile of
the drug [15]. This is characterised by selective inhibition
of dopaminergic activity in the mesolimbic pathway, with
very little inhibition of the nigrostriatal dopaminergic
neurons [16,17]. This affinity profile provides antipsy-
chotic effectiveness without the level of extrapyramidal
symptoms seen with conventional agents [18].
The present study methodology does not enable us to esti-
mate how many patients within the overall population
suffering from schizophrenia would respond in a simi-
larly effective way to sertindole. In addition, the study
does not permit us to establish a profile of the patients
who may respond particularly well to sertindole, as our
sample was small and not representative of the overall
population suffering from schizophrenia. It would be
interesting for further studies to investigate if these
patients who respond particularly well to sertindole have
specific clinical characteristics, thus enabling targeted pre-
scription.
Conclusion
Patients included in this study showed a significant
improvement of psychotic symptoms when treated with
sertindole after failure of another antipsychotic. This
study results have therefore been used for the response to
the authorities, as providing evidence that there is indeed
a subset of patients who benefit from sertindole after
other antipsychotics, including clozapine, have failed.
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